Patents protecting biotechnological invention are becoming ever more important. Because biotechnology has many differences with respect to other technologies, lessons learned in other fields of technology cannot simply be transferred to adopt a suitable strategy for dealing with biotechnology inventions.In this volume, general aspects of biopatent law will be discussed. This involves questions of patentability, including ethical issues and issues of technicality, as well as questio...

**How genomics, big data, and digital technology are revolutionizing every aspect of medicine, from physical exams to drug prescriptions to organ transplants“The Creative Destruction of Medicine should be required reading by all physicians and in all medical schools. It is simply that good.” —Forbes**Technology dominates our lives, and personal genomics is revolutionizing biology. But despite the availability of technologies that can provide virtual, perso...

**The essential guide to how digital technology enables all of us to take charge of our health“Dr. Topol’s vision is compelling, combining an empowering view of technology with the recognition that medicine requires something more.”―Wall Street Journal**A trip to the doctor is almost a guarantee of misery: you make an appointment months in advance, wait for several hours when you arrive, talk to a doctor for fifteen minutes, then wait longer for lab tests, the resu...

An essential book to understanding whether the new miracle cure is good science or simply too good to be trueAmerican taxpayers spend $30 billion annually funding biomedical research, but over half of these studies can't be replicated due to poor experimental design, improper methods, and sloppy statistics. Bad science doesn't just hold back medical progress, it can sign the equivalent of a death sentence for terminal patients. In Rigor Mortis, Richard Har...

The past decade has seen a massive paradigm shift in how new drugs and other therapies are discovered, developed and commercialized. This new distributed model of networked R&D seamlessly blends external partnerships with in-house efforts to generate innovations and create value. Smaller companies and academia have been both beneficiaries and targets of this shift in focus. Partnering with giant pharmaceutical corporations can provide the resources and channels to market that an academ...

The Future of Drug Discovery: Who decides which diseases to treat? provides a timely and detailed look at the efforts of the pharmaceutical industry and how they relate, or should relate, to societal needs. The authors posit that as a result of increasing risk aversion and accelerated savings in research and development, the industry is not developing drugs for increasingly prevalent diseases, such as Alzheimer's disease, untreatable pain, antibiotics and more. This book carefully exposes ...

Scientific and technological innovations are forcing the inadequacies of patent law into the spotlight. Robin Feldman explains why patents are causing so much trouble. She urges lawmakers to focus on crafting rules that anticipate future bargaining, not on the impossible task of assigning precise boundaries to rights when an invention is new.

This book bridges the gap between practitioners of supply-chain management and pharmaceutical industry experts. It aims to help both these groups understand the different worlds they live in and how to jointly contribute to meaningful improvements in supply-chains within the globally important pharmaceutical sector. Scientific and technical staff must work closely with supply-chain practitioners and other relevant parties to help secure responsive, cost effective and risk mitigated supply ...

Retail shelf management means cost-efficiently aligning retail operations with consumer demand. As consumers expect high product availability and low prices, and retailers are constantly increasing product variety and striving towards high service levels, the complexity of managing retail business and its operations is growing enormously. Retailers need to match consumer demand with shelf supply by balancing variety (number of products) and service levels (number of items of a product), an...

The phenomenal growth of global pharmaceutical sales and the quest for innovation are driving an unprecedented search for human test subjects, particularly in middle- and low-income countries. Our hope for medical progress increasingly depends on the willingness of the world's poor to participate in clinical drug trials. While these experiments often provide those in need with vital and previously unattainable medical resources, the outsourcing and offshoring of trials also create new prob...

The forces that shape America's most powerful consumer agencyBecause of the importance of what it regulates, the FDA comes under tremendous political, industry, and consumer pressure. But the pressure goes far beyond the ordinary lobbying of Washington trade groups. Its mandate-one quarter of the national economy-brings the FDA into the middle of some of the most important and contentious issues of modern society. From "designer" babies and abortion to the price of...

Business Development in the biotechnology and pharmaceutical industries accounts for over $5 billion in licensing deal value per year and much more than that in the value of mergers and acquisitions. Transactions range from licences to patented academic research, to product developments as licences, joint ventures and acquisition of intellectual property rights, and on to collaborations in development and marketing, locally or across the globe. Asset sales, mergers and corporate takeovers ...